Market Indices
Sector Heatmap
PCVX — Vaxcyte, Inc. Common Stock
NasdaqVaxcyte, Inc. Common Stock
- O
- 65.86
- H
- 67.15
- L
- 64.27
- V
- 11.53M
PCVX — Latest News & Headlines
20 StoriesVaxcyte Shares Rise 50% After VAX-31 Meets Primary Endpoints in Phase 3 Trial - Yahoo Finance
Vaxcyte Shares Rise 50% After VAX-31 Meets Primary Endpoints in Phase 3 Trial Yahoo Finance
PCVX Stock Jumps As Traders Brace For OPUS-1 Catalyst - Timothy Sykes
PCVX Stock Jumps As Traders Brace For OPUS-1 Catalyst Timothy Sykes
Stocks making the biggest moves midday: Microsoft, SpaceX, Vaxcyte, Banco Bradesco, DraftKings & more - CNBC
Stocks making the biggest moves midday: Microsoft, SpaceX, Vaxcyte, Banco Bradesco, DraftKings & more CNBC
Guggenheim raises Vaxcyte stock price target on vaccine trial win - Investing.com
Guggenheim raises Vaxcyte stock price target on vaccine trial win Investing.com
Small Biotech Squares Up To Pfizer, Merck In $7 Billion Market - Investor's Business Daily
Small Biotech Squares Up To Pfizer, Merck In $7 Billion Market Investor's Business Daily
Two proposed $500 million offerings could fund Vaxcyte vaccine trials and U.S. launch preparations. - Stock Titan
Two proposed $500 million offerings could fund Vaxcyte vaccine trials and U.S. launch preparations. Stock Titan
PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit ‘Blue-Sky’ Case - Stocktwits
PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit ‘Blue-Sky’ Case Stocktwits
Vaxcyte Stock Hits New 52-Week High - Here’s Why - Vaxcyte (NASDAQ:PCVX) - Benzinga
Vaxcyte Stock Hits New 52-Week High - Here’s Why - Vaxcyte (NASDAQ:PCVX) Benzinga
Vaxcyte Stock Spikes 27% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck - Barron's
Vaxcyte Stock Spikes 27% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck Barron's
PCVX Stock Jumps As Traders Brace For OPUS-1 Catalyst - StocksToTrade
PCVX Stock Jumps As Traders Brace For OPUS-1 Catalyst StocksToTrade
Vaxcyte Surges on Positive Phase 3 VAX-31 Trial Readout - Quiver Quantitative
Vaxcyte Surges on Positive Phase 3 VAX-31 Trial Readout Quiver Quantitative
Vaxcyte, Inc. - Common Stock (Nasdaq:PCVX) Stock Quote - FinancialContent
Vaxcyte, Inc. - Common Stock (Nasdaq:PCVX) Stock Quote FinancialContent
About $500 million is expected from stock and $500 million from bonds. Vaxcyte plans to fund vaccine work. - Stock Titan
About $500 million is expected from stock and $500 million from bonds. Vaxcyte plans to fund vaccine work. Stock Titan
PCVX Stock Builds Tension Ahead Of Key OPUS-1 Data - Timothy Sykes
PCVX Stock Builds Tension Ahead Of Key OPUS-1 Data Timothy Sykes
Vaxcyte PCVX Stock Heats Up Ahead OPUS-1 Data - StocksToTrade
Vaxcyte PCVX Stock Heats Up Ahead OPUS-1 Data StocksToTrade
Vaxcyte shares surge on late-stage vaccine trial success - Yahoo Finance
Vaxcyte shares surge on late-stage vaccine trial success Yahoo Finance
An officer proposes selling Vaxcyte (PCVX) shares acquired by exercising stock options for cash. - Stock Titan
An officer proposes selling Vaxcyte (PCVX) shares acquired by exercising stock options for cash. Stock Titan
PCVX Stock Heats Up As OPUS-1 Catalyst Looms Large - StocksToTrade
PCVX Stock Heats Up As OPUS-1 Catalyst Looms Large StocksToTrade
Trial data on a vaccine designed to prevent bacterial pneumonia are set for Oct. 5. Vaxcyte will present them. - Stock Titan
Trial data on a vaccine designed to prevent bacterial pneumonia are set for Oct. 5. Vaxcyte will present them. Stock Titan
Vaxcyte stock falls on $1B dual offering launch - Investing.com
Vaxcyte stock falls on $1B dual offering launch Investing.com